Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (ENVB) is a pioneering biotechnology company committed to the development of innovative neuroplastogenic small-molecule therapeutics aimed at treating mental health conditions such as depression, anxiety, and addiction disorders. Headquartered in the United States, Enveric is at the forefront of mental health research, with a focus on non-hallucinogenic solutions.
The company's flagship program, EB-003, represents a novel approach to tackling challenging mental health disorders. Unlike traditional treatments, EB-003 promotes neuroplasticity without causing hallucinations, providing a safer and potentially more effective option for patients.
Another key project in Enveric's pipeline is EB-002, previously known as EB-373. This next-generation synthetic prodrug of psilocin is being developed to offer new hope in the treatment of psychiatric disorders. With an emphasis on rigorous scientific research and clinical trials, Enveric strives to deliver breakthrough therapies that can significantly improve patients' quality of life.
Enveric's strategic vision includes forming partnerships and collaborations to enhance its research capabilities and accelerate the development of its therapeutic programs. Highlighting its commitment to innovation, the company is also investing in cutting-edge technologies such as artificial intelligence (AI) to further its research and development efforts.
Financially, Enveric Biosciences has been transparent about its funding efforts, ensuring that it maintains a robust financial foundation to support its research initiatives. With a strong commitment to ethical practices and patient-centric solutions, Enveric is emerging as a key player in the biotech sector, focused on addressing some of the most pressing mental health challenges of our time.
Enveric Biosciences (NASDAQ: ENVB) announced plans to launch a first-in-human clinical trial for its lead candidate, EB-373, in Q4 2023. This proprietary psilocin prodrug targets anxiety disorders and has been designated as a New Chemical Entity by Australia’s Therapeutic Goods Administration. Enveric has partnered with Avance Clinical, an experienced contract research organization, to manage the trial, which will evaluate EB-373's safety and tolerability through a multi-cohort, dose-ascending approach. The company aims to innovate treatment options for anxiety, capitalizing on its Psybrary drug discovery platform.
Enveric Biosciences (NASDAQ: ENVB) announced groundbreaking research detailing the isolation of a novel indolethylamine N-methyltransferase from the cane toad (Rhinella marina). This discovery enables a new bioproduction platform for developing psychedelic-inspired drug candidates aimed at treating psychiatric disorders like anxiety and depression. The research was conducted by the University of Calgary and led by Dr. Peter Facchini. Enveric aims to begin human clinical trials for their lead product, EB-373, for anxiety treatment, reflecting their commitment to innovate in mental health therapeutics.
Enveric Biosciences (NASDAQ: ENVB) has appointed Kevin Coveney, CPA, as Chief Financial Officer effective March 13, 2023. With over 30 years of experience in finance and operations within the biotechnology sector, Coveney aims to lead the company's financial and capital market activities. He has a proven track record of executing growth strategies in previous roles at various biotech firms. Coveney's appointment comes at a crucial time as Enveric advances its EVM201 and EVM301 product series targeting mental health issues. As part of his induction, Coveney will receive restricted stock units convertible to 26,500 shares.
Enveric Biosciences (NASDAQ: ENVB) announced the appointment of Lynn Gallant as Vice President, Clinical Operations, effective February 22, 2023. Gallant brings over 25 years of experience in clinical operations and trial management, previously holding leadership roles at BlueRock Therapeutics and Bioverativ. She will oversee the clinical development of Enveric’s EVM201 and EVM301 product platforms. The company plans to initiate a clinical trial for its lead drug candidate, EB-373, targeting anxiety disorders. Enveric's focus is on developing novel therapeutics for mental health, leveraging its unique Psybrary™ drug discovery platform.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on developing small-molecule therapeutics for anxiety, depression, and addiction disorders, announces CEO
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on innovative therapeutics for mental health disorders, announced CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference from February 6-9, 2023, in New York City. The presentation on February 6 at 3:00 p.m. EST will highlight the company's clinical development strategy and recent achievements. Enveric aims to address anxiety, depression, and addiction through its proprietary platform, The Psybrary™, with a focus on its EVM201 Series, particularly the EB-373 treatment for anxiety disorders. One-on-one investor meetings will also take place during the conference.
Enveric Biosciences (NASDAQ: ENVB) announced its participation at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during the 41st Annual J.P. Morgan Health Care Conference in San Francisco from January 9-12, 2023. Dr. Joseph Tucker, CEO, will present the company's advancements in therapeutics addressing anxiety, depression, and addiction disorders. The Neuroscience Forum presentation is scheduled for January 8 at 1:30 PM PT, while the Biotech Showcase will take place on January 10 at 10:00 AM PT. Enveric leverages its unique Psybrary™ platform to develop innovative small-molecule therapeutics.
Enveric Biosciences (NASDAQ: ENVB) announced the confidential submission of a Form S-1 draft registration statement to the SEC for a spin-off of its cannabinoid pipeline into a subsidiary named Akos Biosciences. The spin-off aims to enhance strategic focus and unlock potential value, allowing each entity to raise capital independently. Shareholders will own a majority of Akos post-separation, which is expected to list on Nasdaq in the first half of 2023. The dividend will be taxable for U.S. federal income purposes.
Enveric Biosciences (NASDAQ: ENVB), a biotech firm focused on developing small-molecule therapeutics for anxiety, depression, and addiction, announced the participation of President & COO Avani Kanubaddi in A.G.P.’s Virtual Biotech Conference from November 30 to December 1, 2022. This conference aims to connect Enveric's management with investors and stakeholders. Interested parties can schedule one-on-one meetings by contacting A.G.P. or KCSA Strategic Communications. For more details, visit www.enveric.com.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on developing innovative therapeutics for anxiety, depression, and addiction, announces CEO Dr. Joseph Tucker's participation in the Wonderland conference in Miami, FL, from November 3-5, 2022. Dr. Tucker will speak on the panel entitled Synthetic vs Natural Debate on November 5 at 12:00 p.m. ET. Interested parties can schedule one-on-one meetings with Enveric's management by contacting KCSA Strategic Communications.
FAQ
What is the current stock price of Enveric Biosciences (ENVB)?
What is the market cap of Enveric Biosciences (ENVB)?
What does Enveric Biosciences specialize in?
What is EB-003?
What is EB-002?
Where is Enveric Biosciences headquartered?
How does Enveric Biosciences fund its research?
Is Enveric involved in any partnerships or collaborations?
How does Enveric ensure its treatments do not cause hallucinations?
What technologies is Enveric investing in?
What are the core values of Enveric Biosciences?
Why is Enveric considered a key player in the biotech sector?
